Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

被引:1740
作者
Hutchins, LF
Unger, JM
Crowley, JJ
Coltman, CA
Albain, KS
机构
[1] Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA
[2] Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98104 USA
[3] Univ Texas, Hlth Sci Ctr, Dept Med Oncol, San Antonio, TX 78284 USA
[4] Loyola Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Maywood, IL 60153 USA
关键词
D O I
10.1056/NEJM199912303412706
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. Methods: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. Results: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P < 0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P < 0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. Conclusions: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation. (N Engl J Med 1999;341:2061-7.) (C)1999, Massachusetts Medical Society.
引用
收藏
页码:2061 / 2067
页数:7
相关论文
共 35 条
  • [1] CARING FOR WOMENS HEALTH - WHAT IS THE PROBLEM
    ANGELL, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (04) : 271 - 272
  • [2] Baquet C, 1986, Prog Clin Biol Res, V216, P215
  • [3] BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369
  • [4] ONCOLOGISTS RELUCTANCE TO ACCRUE PATIENTS ONTO CLINICAL-TRIALS - AN ILLINOIS CANCER CENTER STUDY
    BENSON, AB
    PREGLER, JP
    BEAN, JA
    RADEMAKER, AW
    ESHLER, B
    ANDERSON, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (11) : 2067 - 2075
  • [5] BONADONNA G, 1992, CANCER RES, V52, P2127
  • [6] Sociodemographic analysis of patients in radiation therapy oncology group clinical trials
    Chamberlain, RM
    Winter, KA
    Vijayakumar, S
    Porter, AT
    Roach, M
    Streeter, O
    Cox, JD
    Bondy, ML
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (01): : 9 - 15
  • [7] CHEMOTHERAPY OF METASTATIC BREAST-CANCER IN THE ELDERLY - THE PIEDMONT-ONCOLOGY-ASSOCIATION EXPERIENCE
    CHRISTMAN, K
    MUSS, HB
    CASE, LD
    STANLEY, V
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (01): : 57 - 62
  • [8] COTTON P, 1993, JAMA-J AM MED ASSOC, V269, P2067
  • [9] CRIVELLARI D, 1998, P AN M AM SOC CLIN, V17, pA102
  • [10] DEES EC, 1998, P AN M AM SOC CLIN, V17, pA103